Clinical Features of ICU Admitted and Intubated Novel Corona Virus-infected Patients in Iran

Farahani, Ramin Hamidi; Gholami, Mohammad; Hazrati, Ebrahim; Rouzbahani, Negin Hosseini; Hejripour, Zia; Soleiman-Meigooni, Saeed; Dadmanesh, Maryam; Noorifard, Mahtab; Kargar, Jalal; Motavalli, Farhad; Laripour, Reza; Nourmohammadi, Abbas; Zargar, Sanaz

doi:10.5812/archcid.103295

Cited by 4 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, some have severe symptoms and even lost their lives. The deteriorating condition of some sufferers is mainly attributed to unbridled inflammatory damage caused by cytokine storm, uncontrolled immune response, leading to acute respiratory distress syndrome (ARDS).On the other hand, systemic inflammation of COVID-19 has a potentially fatal side effect in patients [ 2 , 3 ]. It seems any factor that regulates the immune system responses can modulate the consequences of COVID-19 infection [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

The effect of IGF-1 plasma concentration on COVID-19 severity

Hazrati

Gholami

Farahani

et al. 2022

Microbial Pathogenesis

Self Cite

View full text Add to dashboard Cite

Background The severity and fatality of Coronavirus disease 2019 (COVID-19) infection are not the same in the infected population. The host immune response and Immune-stimulating factors appear to play a role in COVID-19 infection outcome. insulin-like growth factor-1 (IGF-1) affects the immune system by controlling the endocrine system. Recently, the effect of IGF-1 levels on COVID-19 prognosis has been considered. Objective To investigate the difference between circulating IGF-1 and inflammatory cytokines concentration among COVID-19 patients, infected patients admitted to the Intensive Care Unit (ICU) (n = 40; 35 ± 5 y) and patients with mild cases of COVID-19 (n = 40; 35 ± 5 y) were screened prior to participation in the study. There was no significant difference between the groups in terms of gender and preexisting inflammatory state. Collected samples were evaluated by ELISA for IGF-1 and IL-6. Results The study outcomes included a significant decrease in IGF-1 and an increase in IL-6 serum concentration, as an inflammatory marker, for infected patients admitted to the Intensive Care Unit (ICU) (P ≤ 0.001). Finally, there was a significant increase in the IGF-1 and a decrease in the IL-6 serum concentration of hospitalized patients. Discussion it appears that inflammatory cytokines (IL-6) serum concentration in the severe form of corona virus-based infections causes reduced defenses because of suppressed IGF-1. Conclusions Our findings show that lower IGF-1 concentrations are associated with a Severe form of COVID-19 disease. It seems, IGF-1 supplementation or anti-inflammatory treatment rescued the severe form of COVID-19 infection. Further studies are required to determine how to design COVID-19 therapeutic strategies targeting the IGF-1 pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of IGF-1 plasma concentration on COVID-19 severity

Hazrati

Gholami

Farahani

et al. 2022

Microbial Pathogenesis

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the study by Zhou et al, the most common symptoms were fever and cough, respectively (13). In other studies, fever and respiratory symptoms were the most common symptoms in hospitalized patients (14,16). Other studies also suggested that pneumonia and respiratory system involvement are the main complications of COVID-19 (4); however, the involvement of other organs is also reported in various studies (17)(18)(19).…”

Section: Discussionmentioning

confidence: 96%

Comparison of Clinical Manifestations and Risk Factors of Death in Two Age Groups Less and More Than 50 Years in Patients with COVID-19

Sharifipour

Koohpaei

Shams

et al. 2021

Arch Clin Infect Dis

View full text Add to dashboard Cite

Background: The COVID-19 pandemic has affected more than 180 countries and has killed more than half a million people up to now. Risk factors for death are not yet fully identified. Objectives: The present study aimed at comparing the clinical manifestations and risk factors for death between two groups of patients with COVID-19 aged under and above 50 in Qom Province, Iran. Methods: The current retrospective cohort study was conducted on 178 patients with COVID-19 in Qom Province. Patients were followed up until recovery or death. The source population was divided into four groups, of which 45 patients were randomly enrolled in the study. The first group included patients aged less than 50 discharged after recovery; the second group included patients less than 50 years who died from COVID-19; the third group consisted of patients above 50 discharged after recovery, and the fourth group included patients above 50 who died from COVID-19. The data, including COVID-19 clinical symptoms and presumptive risk factors for death, were collected and compared between groups. Results: The most common symptoms in hospitalized patients were shortness of breath (82.6%), cough (73.6%), and fever (71.9%), respectively. In the age group above 50, the prevalence of fever in the recovered subjects was higher than that of the ones who died from the disease (81.8% Vs. 53.3%). Headache and loss of senses of smell and taste were also more common in both age groups in the recovered subjects. In the age group under 50, subjects who died had higher BMI values, but in the age group above 50, subjects who died had lower BMIs. Conclusions: The results of the present study showed that obesity could be a risk factor for death in the age group under 50. The results also indicated that in both age groups, extrapulmonary symptoms were more common in recovered patients.

show abstract

“…The clinical manifestation of COVID-19 ranges from asymptomatic, mild pneumonia to acute serious respiratory failure, septic shock, and multiple organ dysfunction syndromes (MODS) [3,4]. Patients with intermediate or severe symptoms and respiratory failure would need to be admitted to ICU [5]. COVID-19 spreads through respiratory droplets or direct contact.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Efficacy of Methylprednisolone Pulse Therapy in Treatment of Covid-19 Adult Patients with Severe Respiratory Failure: Randomized, Clinical Trial

Farahani

Mosaed

Nezami-Asl

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Covid-19 is now global concern and widely spread to the world due to high mortality among the nations we tried to evaluate the efficacy of methylprednisolone pulse in COVID-19 patients with severe respiratory failure.Methods: This study was phase2, double-blind, randomized, clinical trial in adults with COVID-19 (aged ≥18 years old) admitted to the intensive care unit (ICU) of *. Patients with intermediate or severe COVID-19 with PaO2/FiO2 less than 300 and progressive disease unresponsive to standard treatments admitted to ICU. Patients were randomly allocated in either control or investigation group. The control group received recommended regimen for COVID-19. The investigation group received the recommended regimen plus Methylprednisolone (1000mg/day for three days) and oral prednisolone 1mg/kg with tapering of dose within ten days. Results: A total of 29 ICU patients with intermediate or severe COVID-19 pneumonia recruited in this study. Fourteen patients (4 female, ten male) allocated in the investigation group, and 15 patients (6 female, nine male) assigned to the control group. The participant’s average age was 64.03±13.545 (case: 61.07±12.83, control: 66.80±14.03). The patients with methylprednisolone pulse had significantly higher systolic (P=0.018) and diastolic (P=0.001) blood pressure, meanwhile, the Glasgow coma scale (GCS) of methylprednisolone group was considerably (P<0.001) higher, and by the improvement in SpO2 of methylprednisolone group none of these patients needed mechanical ventilation.Conclusion: This study demonstrated methylprednisolone pulse in COVID-19 severe respiratory failure dramatically improves the clinical condition of patients including, GCS, and SpO2 of patients.Clinical Trial Registration Number: IRCT20200406046963N1

show abstract

Clinical Features of ICU Admitted and Intubated Novel Corona Virus-infected Patients in Iran

Cited by 4 publications

References 13 publications

The effect of IGF-1 plasma concentration on COVID-19 severity

The effect of IGF-1 plasma concentration on COVID-19 severity

Comparison of Clinical Manifestations and Risk Factors of Death in Two Age Groups Less and More Than 50 Years in Patients with COVID-19

Evaluation of the Efficacy of Methylprednisolone Pulse Therapy in Treatment of Covid-19 Adult Patients with Severe Respiratory Failure: Randomized, Clinical Trial

Contact Info

Product

Resources

About